|
CN109456410B
(zh)
*
|
2007-04-03 |
2022-01-28 |
安进研发（慕尼黑）股份有限公司 |
跨物种特异性CD3-ε结合结构域
|
|
EP4180458A1
(en)
*
|
2008-10-01 |
2023-05-17 |
Amgen Research (Munich) GmbH |
Cross-species-specific psma x cd3 bispecific single chain antibody
|
|
US10981998B2
(en)
*
|
2008-10-01 |
2021-04-20 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
CA2769444A1
(en)
|
2009-05-19 |
2010-11-25 |
Aic Blab Company |
Composite current collector and methods therefor
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
TWI653333B
(zh)
*
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
CN105585630B
(zh)
|
2010-07-29 |
2020-09-15 |
Xencor公司 |
具有修改的等电点的抗体
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
MX349057B
(es)
|
2010-11-30 |
2017-07-07 |
Chugai Pharmaceutical Co Ltd |
Agente terapeutico que induce citotoxicidad.
|
|
EP2699596A4
(en)
*
|
2011-04-22 |
2015-01-14 |
Emergent Product Dev Seattle |
PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
US20130058936A1
(en)
*
|
2011-08-23 |
2013-03-07 |
Peter Bruenker |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
US20150037334A1
(en)
*
|
2012-03-01 |
2015-02-05 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
HK1215950A1
(zh)
*
|
2012-09-25 |
2016-09-30 |
艾科诺斯科技股份有限公司 |
异源二聚免疫球蛋白的纯化
|
|
CA2890166C
(en)
*
|
2012-11-06 |
2023-08-15 |
Bayer Pharma Aktiengesellschaft |
Formulation for bispecific t-cell engagers (bites)
|
|
CN103087171B
(zh)
*
|
2012-12-24 |
2015-01-14 |
中国人民解放军第四军医大学 |
一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
DK2943511T3
(da)
|
2013-01-14 |
2019-10-21 |
Xencor Inc |
Nye heterodimeriske proteiner
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
EP2953974B1
(en)
|
2013-02-05 |
2017-12-20 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and bcma
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
JO3529B1
(ar)
*
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
WO2014143886A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Edimer Pharmaceuticals, Inc. |
Anti-ectodysplasin antibodies
|
|
JP6404313B2
(ja)
*
|
2013-03-15 |
2018-10-10 |
アムジエン・インコーポレーテツド |
ヘテロ二量体性二重特異性抗体
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014140368A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza m2 and cd3
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
RU2727836C2
(ru)
|
2013-07-25 |
2020-07-24 |
Сайтомкс Терапьютикс, Инк. |
Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
|
|
BR112016022385A2
(pt)
|
2014-03-28 |
2018-06-19 |
Xencor, Inc |
anticorpos específicos que se ligam a cd38 e cd3
|
|
US9212225B1
(en)
*
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
EP3164417A1
(en)
|
2014-07-01 |
2017-05-10 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
BR112017001579A2
(pt)
*
|
2014-07-25 |
2017-11-21 |
Cytomx Therapeutics Inc |
anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
|
|
KR102689285B1
(ko)
|
2014-11-26 |
2024-07-31 |
젠코어 인코포레이티드 |
Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CN107406512A
(zh)
|
2014-11-26 |
2017-11-28 |
Xencor公司 |
结合cd3和cd38的异二聚体抗体
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
LT3247725T
(lt)
|
2015-01-23 |
2020-10-12 |
Sanofi |
Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123
|
|
EP3256495A4
(en)
*
|
2015-02-11 |
2018-09-19 |
Aptevo Research and Development LLC |
Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
EP3932428A1
(en)
|
2015-05-21 |
2022-01-05 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
CN114652827A
(zh)
*
|
2015-05-29 |
2022-06-24 |
安普希韦纳治疗公司 |
双特异性cd33和cd3结合蛋白质的使用方法
|
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
HRP20200390T1
(hr)
|
2015-08-03 |
2020-06-12 |
Engmab Sàrl |
Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
|
|
UA127515C2
(uk)
|
2015-08-17 |
2023-09-20 |
Янссен Байотек, Інк. |
Антитіло до всма, біспецифічна антигензв'язувальна молекула, що зв'язує всма і cd3, і їх використання
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
CN105198992B
(zh)
*
|
2015-10-16 |
2018-07-13 |
中国人民解放军海军总医院 |
一种人源抗创伤弧菌溶血素蛋白(vvh)抗体的制备方法与应用
|
|
EA201891084A1
(ru)
|
2015-11-02 |
2019-10-31 |
|
Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
|
|
AU2016365742A1
(en)
|
2015-12-07 |
2018-06-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
|
HUE060504T2
(hu)
*
|
2016-02-03 |
2023-03-28 |
Amgen Res Munich Gmbh |
PSMA és CD3 bispecifikus T-sejthez kötõ ellenanyag-konstrukciók
|
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
IL263102B2
(en)
|
2016-05-20 |
2023-11-01 |
Harpoon Therapeutics Inc |
A serum albumin-binding protein with a single site
|
|
US10787518B2
(en)
|
2016-06-14 |
2020-09-29 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
WO2017223111A1
(en)
|
2016-06-21 |
2017-12-28 |
Teneobio, Inc. |
Cd3 binding antibodies
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
TWI781108B
(zh)
|
2016-07-20 |
2022-10-21 |
比利時商健生藥品公司 |
抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
MY200988A
(en)
*
|
2016-09-14 |
2024-01-27 |
Teneobio Inc |
CD3 Binding Antibodies
|
|
IL265484B1
(en)
|
2016-09-21 |
2025-09-01 |
Aptevo Res & Development Llc |
Cd123 binding proteins and related compositions and methods
|
|
SG11201903302UA
(en)
|
2016-10-14 |
2019-05-30 |
Xencor Inc |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
|
|
IL266424B2
(en)
|
2016-11-02 |
2023-09-01 |
Engmab Sarl |
A bispecific antibody against bcma and cd3 and an immunological drug for combined treatment in multiple myeloma
|
|
US10849973B2
(en)
|
2016-11-23 |
2020-12-01 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
|
KR20190087539A
(ko)
*
|
2016-11-23 |
2019-07-24 |
하푼 테라퓨틱스, 인크. |
Psma 표적화 삼중특이성 단백질 및 사용 방법
|
|
EP3559035A1
(en)
|
2016-12-21 |
2019-10-30 |
TeneoBio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
TWI676681B
(zh)
*
|
2017-03-29 |
2019-11-11 |
臺北醫學大學 |
具抗原專一性的t細胞及其用途
|
|
KR102376863B1
(ko)
|
2017-05-12 |
2022-03-21 |
하푼 테라퓨틱스, 인크. |
메소텔린 결합 단백질
|
|
CN118146370A
(zh)
|
2017-06-20 |
2024-06-07 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
CA3067584A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneobio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
EP3642229A1
(en)
|
2017-06-21 |
2020-04-29 |
Gilead Sciences, Inc. |
Multispecific antibodies that target hiv gp120 and cd3
|
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
|
UY37829A
(es)
|
2017-08-03 |
2019-01-31 |
Amgen Inc |
Muteínas de interleucina 21 y métodos de tratamiento
|
|
ES2928576T3
(es)
|
2017-09-08 |
2022-11-21 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos de uso de los mismos
|
|
TWI820041B
(zh)
|
2017-09-21 |
2023-11-01 |
中國大陸商上海藥明生物技術有限公司 |
新型抗CD3ε抗體
|
|
US12486325B2
(en)
|
2017-09-21 |
2025-12-02 |
WuXi Biologics Ireland Limited |
Anti-CD3epsilon antibodies
|
|
CN111630070B
(zh)
|
2017-10-13 |
2024-07-30 |
哈普恩治疗公司 |
三特异性蛋白质及使用方法
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
BR112020007309A2
(pt)
|
2017-10-14 |
2020-09-29 |
Cytomx Therapeutics, Inc. |
anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US10426424B2
(en)
|
2017-11-21 |
2019-10-01 |
General Electric Company |
System and method for generating and performing imaging protocol simulations
|
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
WO2019126756A1
(en)
|
2017-12-22 |
2019-06-27 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd22
|
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
|
MA51631A
(fr)
|
2018-01-12 |
2020-11-18 |
Amgen Inc |
Anticorps anti-pd1 et méthodes de traitement
|
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
JP7724061B2
(ja)
|
2018-04-11 |
2025-08-15 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用
|
|
CN112867734A
(zh)
|
2018-04-18 |
2021-05-28 |
Xencor股份有限公司 |
包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
|
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
|
|
AU2019271138A1
(en)
|
2018-05-14 |
2021-01-07 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
MX2020012286A
(es)
|
2018-05-16 |
2021-04-28 |
Janssen Biotech Inc |
Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t.
|
|
JOP20190116A1
(ar)
|
2018-05-24 |
2019-11-24 |
Janssen Biotech Inc |
الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
|
|
JOP20200303A1
(ar)
|
2018-05-24 |
2020-11-23 |
Janssen Biotech Inc |
عوامل ربط psma واستخداماتها
|
|
EP3802611A2
(en)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Binding molecules against bcma and uses thereof
|
|
US11555071B2
(en)
|
2018-06-03 |
2023-01-17 |
Lamkap Bio Beta Ltd. |
Bispecific antibodies against CEACAM5 and CD47
|
|
TW202035451A
(zh)
|
2018-07-24 |
2020-10-01 |
美商英伊布里克斯公司 |
含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
|
|
HRP20230115T1
(hr)
*
|
2018-07-31 |
2023-06-09 |
Heidelberg Pharma Research Gmbh |
Humanizirana antitijela protiv psma
|
|
US12460000B2
(en)
|
2018-09-07 |
2025-11-04 |
Itabmed (Hk) Limited |
Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
CN113166263A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
Dll3单域抗体及其治疗性组合物
|
|
SG11202109406TA
(en)
|
2019-03-01 |
2021-09-29 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
EA202192736A1
(ru)
|
2019-04-05 |
2022-01-27 |
Тенеобио, Инк. |
Антитела, содержащие только тяжелые цепи, которые связываются с псма
|
|
CA3136888A1
(en)
*
|
2019-04-19 |
2020-10-22 |
Janssen Biotech, Inc. |
Methods of treating prostate cancer with an anti- psma/cd3 antibody
|
|
KR20220002900A
(ko)
*
|
2019-04-19 |
2022-01-07 |
얀센 바이오테크 인코포레이티드 |
항-psma/cd3 항체로 신장암을 치료하는 방법
|
|
CU20210096A7
(es)
|
2019-05-21 |
2022-06-06 |
Novartis Ag |
Moléculas de unión a cd19
|
|
PH12021553145A1
(en)
|
2019-06-14 |
2022-07-25 |
Teneobio Inc |
Multispecific heavy chain antibodies binding to cd22 and cd3
|
|
TWI809286B
(zh)
|
2019-07-05 |
2023-07-21 |
日商小野藥品工業股份有限公司 |
以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
|
|
EP4004209A2
(en)
*
|
2019-07-26 |
2022-06-01 |
Ixaka France |
Anti-cd3 aptamers for use in cell targeting and labeling
|
|
KR20220113353A
(ko)
|
2019-09-18 |
2022-08-12 |
람캅 바이오 알파 에이지 |
Ceacam5 및 cd3에 대한 이중특이적 항체
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
EP3842461A1
(en)
|
2019-12-23 |
2021-06-30 |
Albert-Ludwigs-Universität Freiburg |
Chimeric antigen receptors that bind to prostate specific membrane antigen
|
|
EP4090368A1
(en)
|
2020-01-13 |
2022-11-23 |
Aptevo Research and Development LLC |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
|
WO2021146328A1
(en)
|
2020-01-13 |
2021-07-22 |
Aptevo Research And Development Llc |
Formulations for protein therapeutics
|
|
WO2021168303A1
(en)
|
2020-02-21 |
2021-08-26 |
Harpoon Therapeutics, Inc. |
Flt3 binding proteins and methods of use
|
|
KR20250007022A
(ko)
|
2020-04-29 |
2025-01-13 |
테네오원, 인코포레이티드 |
변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
|
|
AU2021272291A1
(en)
|
2020-05-11 |
2023-02-02 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
KR20230166150A
(ko)
|
2020-08-19 |
2023-12-06 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
|
CA3194771A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
|
|
WO2022081822A1
(en)
*
|
2020-10-15 |
2022-04-21 |
Janux Therapeutics, Inc. |
Antibodies targeting psma and cd3 and uses thereof
|
|
IL302586A
(en)
*
|
2020-11-06 |
2023-07-01 |
Amgen Res Munich Gmbh |
Polypeptide constructs selectively binding to cldn6 and cd3
|
|
EP4240768A2
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
US11555078B2
(en)
|
2020-12-09 |
2023-01-17 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens
|
|
CA3211163A1
(en)
|
2021-02-16 |
2022-08-25 |
Janssen Pharmaceutica Nv |
Trispecific antibody targeting bcma, gprc5d, and cd3
|
|
WO2022192403A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
EP4314070A1
(en)
|
2021-03-24 |
2024-02-07 |
Janssen Biotech, Inc. |
Trispecific antibody targeting cd79b, cd20, and cd3
|
|
JP2024517701A
(ja)
|
2021-04-29 |
2024-04-23 |
アムジエン・インコーポレーテツド |
組換え生産タンパク質の低分子量種を低減させる方法
|
|
IL307672A
(en)
|
2021-05-06 |
2023-12-01 |
Amgen Res Munich Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
JP2024519964A
(ja)
|
2021-05-21 |
2024-05-21 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
タンパク質治療薬のための投薬レジメン
|
|
CN115536740A
(zh)
*
|
2021-06-30 |
2022-12-30 |
苏州方德门达新药开发有限公司 |
介导细胞内有效滞留cd3的空间构象表位及其应用
|
|
JP7707824B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707832B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707836B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707834B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707825B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707821B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707833B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707823B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707820B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707830B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707827B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707835B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707822B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707828B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707831B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
JP7707829B2
(ja)
*
|
2021-10-06 |
2025-07-15 |
株式会社三洋物産 |
遊技機
|
|
CA3237357A1
(en)
|
2021-11-03 |
2023-05-11 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
|
|
EP4496814A1
(en)
|
2022-03-21 |
2025-01-29 |
Amgen Inc. |
Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
|
|
CN119137147A
(zh)
|
2022-05-12 |
2024-12-13 |
安进研发（慕尼黑）股份有限公司 |
具有增加的选择性的多链多靶向性双特异性抗原结合分子
|
|
WO2025134049A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
|
|
WO2025134050A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
|